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Abstract
BACKGROUND—Cellular markers help identify different components of a pathological process
and may contribute to the diagnosis, prognostic assessment, and management of patients with
suspected syndromes. Flow cytometry can be used to accurately assess markers of platelet and
leukocyte activation and cellular aggregation in whole blood. To use cell markers as predictors of
disease requires that they be measured reliably and show modest within-individual, day-to-day
variation.
METHODS—We used whole blood flow cytometry to analyze monocyte and platelet markers in
the Atherosclerosis Risk in Communities (ARIC) Carotid MRI study. We estimated laboratory
variability using 20 split samples, process variation using replicate blood tubes taken from 112
subjects, and biologic plus process variation using replicate blood samples taken 4-8 weeks apart
from 55 people.
RESULTS—For most analytes, the laboratory CV was <10% (mean 3.6%, range 0%-14.5%) and
reliability was excellent (75% of analytes had R > 0.90). Reliability coefficients based on repeat-
visit data indicated substantial to high repeatability (R > 0.60) for CD14, Toll-like receptor (TLR)-2,
CD162, CD61, CD41, CD62P, CD154, and platelet-leukocyte aggregates. In contrast, TLR-4, CD45,
myeloperoxidase (MPO), and cyclooxygenase (COX)-2 had slight to moderate repeat visit reliability.
CONCLUSIONS—The high repeatability results for selected platelet and monocyte markers
indicate that they can be reliably measured in multicenter studies with delayed sample processing,
provided that rigorous standardization of sample collection, shipping, and flow cytometry procedures
is applied.
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Large prospective cohort studies have been critical in identifying major risk factors for
cardiovascular disease, including increased blood pressure, dyslipidemia, smoking, and
diabetes. In recent years, the focus of basic and epidemiologic investigations has shifted to
factors or mechanisms involved in the early subclinical phases of atherosclerosis. This research
suggests that many types of inflammatory cells and their activation markers play an important
role in the formation and progression of atherosclerosis (1-4).
Patients with carotid atherosclerosis were reported to have an increased expression of
cyclooxygenase 2 (COX-2)5 simultaneously in peripheral blood mononuclear cells and in the
vulnerable plaque regions (5). It was suggested that myeloperoxidase (MPO), a leukocyte
enzyme that promotes oxidative damage of host tissues at sites of inflammation, including
atherosclerotic lesions, might help in risk stratification for cardiovascular disease (5-7). Recent
studies have demonstrated the presence of the Toll-like receptors (TLRs) in both human
plaques and murine models of atherosclerosis (8). Members of the TLR family play a critical
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Increased platelet activation is central to the pathophysiology of arterial thrombosis (11), and
several platelet-derived factors may be involved in the inflammatory interaction between
platelets, leukocytes, and endothelial cells (12,13). Platelet P-selectin interacts with P-selectin
glycoprotein ligand 1 (PSGL-1) on leukocytes to form platelet-leukocyte aggregates. It has
been suggested that platelet-leukocyte aggregates may be a sensitive marker of platelet
activation and a good reflection of ongoing vascular thrombosis and inflammation (14,15).
Immunophenotyping by flow cytometry has become standard practice for identification of
human leukocyte subpopulations (16-18) and is increasingly used to characterize the
phenotypic alterations of platelets (19-21). Methods for measuring monocyte and platelet
markers are relatively easy to apply in a single-center study. A major problem in assessing
blood platelet and leukocyte markers in multicenter studies is that activation can occur due to
delays in processing. Many clinical laboratories, particularly reference facilities, face this same
problem. To prevent activation, careful blood collection, storage/shipment, and processing
conditions are important. Studies and recommendations have been published addressing the
sources of variation in multicenter studies (22-26), but they largely relate to flow cytometric
lymphocyte immunophenotyping for hematologic malignancies or HIV/AIDS. The major
focus of the Atherosclerosis Risk in Communities (ARIC) Carotid MRI study was the reliability
of flow cytometric platelet and monocyte measures.
To test the possibility that increased levels of monocyte activation and increased leukocyte-
platelet interactions may increase the risk of atherosclerosis, one needs the ability to accurately
rank individuals on these characteristics. Analytes with large variability involving blood
collection, processing, and analysis and within-person variability are unlikely to show
significant associations with risk factors or disease outcomes. In addition, biased regression
coefficients may result from modeling the association between analytes with high variability
(27).
The aim of this study was to quantify the sources of variation in flow cytometry measurements
of platelet and monocytes (variation in the drawing or processing of blood, in the quality of
the blood sample after shipment to the central laboratory, in reagents, between technicians
performing the measurements, and over time within an individual). In this study, we refer to
sources of variability that involve blood collection, processing, and analysis as “method
variability,” the magnitude of which has important implications for detecting association with
disease. We collected replicate blood samples during the course of the ARIC Carotid MRI
study to assess the magnitude of variation in flow cytometry measurements and enable
correction of measurement error during data analysis.
Materials and Methods
STUDY POPULATION
The ARIC study is a multicenter, cohort study of atherosclerosis and its sequelae among
African American and white men and women from 4 US communities: Forsyth County, North
Carolina; Jackson, Mississippi; suburban Minneapolis, Minnesota; and Washington County,
Maryland (28). The ARIC Carotid MRI study, which enrolled participants from the ARIC
cohort, was designed to further improve our understanding of cellular factors by examining
the association of markers of platelet and monocyte activation and cellular aggregation with
atherosclerotic plaque characteristics and early pathologic changes in the carotid arterial wall.
We used flow cytometry to measure platelet and monocyte markers and cell aggregates in
stabilized whole blood.
The study population consisted of 2066 men and women recruited from the ARIC study under
a stratified sampling plan designed to enrich for the presence of visible plaque while allowing
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for population-based parameter estimates. The study was approved by the Institutional Review
Boards of the 4 participating centers.
BLOOD SAMPLING FOR FLOW CYTOMETRY
All technicians performing venipuncture were centrally trained using a common protocol,
followed by a period of supervised practice and certification (29). Samples for flow cytometry
were collected in Cyto-Chex® BCT Vacutainer Tubes (Streck) and mixed with anticoagulant
by inverting gently 8 times. Cyto-Chex tubes, blood collection tubes for immunotyping by
flow cytometry, contain a combination of EDTA and a cell membrane stabilizer for blood cells
(30,31). The samples were shipped on the day of blood draw in insulated styrofoam containers
with temperature-stabilizing packages (approximate specimen temperature 10-15 °C) by
overnight courier to the flow cytometry laboratory (ARIC Carotid MRI Study Manual 2: Field
Center Procedures. Biospecimen Collection and Processing, p. 55,
www.cscc.unc.edu/carmri). Before initiation of the ARIC Carotid MRI study, we carried out
multiple protocol-development studies and documented the stability of the flow cytometry
measurements when the samples were shipped and received within 24 h. Immediately on
receipt, samples were prepared for analysis according to the procedures described below.
MONOCLONAL ANTIBODIES
We used 11 monoclonal antibodies to label monocyte and platelet markers: phycoerythrin-
cyanin 5.1-conjugated CD14 (CD14-PC5), CD45-PC5, fluorescein isothiocyanate-conjugated
CD41 (CD41-FITC), CD61-FITC, phycoerythrin-conjugated CD62 (CD62P-PE, or P-
selectin), CD154-PE (CD40 ligand, or CD40L), MPO-FITC (all Beckman Coulter), CD162-
PE (PSGL-1; BD Biosciences), TLR-2-FITC, TLR-4-PE (both Ebioscience), and COX-2-
FITC (Cayman Chemical).
THREE-COLOR STAINING FOR MONOCYTE/LEUKOCYTE SURFACE MARKERS
We prepared samples using the PrepPlus™ 2 Workstation (Beckman Coulter). Briefly, for the
CD14/CD41/TLR-4 protocol, we placed 100 μL whole blood, 10 μL CD14-PC5, 20 μL CD41-
FITC, and 20 μL TLR-4-PE into a 12-by-75-mm tube (Falcon; Fisher Scientific) and incubated
them for 20 min in the dark at room temperature. We then placed the tube into a Coulter TQ-
Prep™ Workstation for addition of lysing, stabilizing, and fixing reagents (ImmunoPrep™;
Beckman Coulter), according to the manufacturer’s instructions. The lysed sample tube was
kept in the dark and analyzed within 1 h. For the CD14/TLR-2/CD162 protocol, we mixed 100
μL blood with 10 μL CD14-PC5, 20 μL TLR-2-FITC, and 20 μL CD162-PE and processed
them in the same manner. We used a tube containing the unstained patient sample and an
isotype control tube to evaluate autofluorescent vs nonspecific binding properties of antibodies.
Two thousand monocyte events, defined as cells with respective side scatter (SSC) and CD14-
PC5 staining characteristics, were acquired in the list mode file from each sample, and
corresponding levels of TLR-2, TLR-4, and PSGL-1 were obtained from the CD14+ cell gate
(Fig. 1). Results were expressed as percentage of positive events gated and median fluorescence
intensity (MFI).
TWO-COLOR MONOCYTE/LEUKOCYTE SURFACE AND INTRACELLULAR STAINING
We processed blood samples in parallel for the CD14/COX-2 and CD45/MPO protocols.
Briefly, 50 μL blood and 10 μL of either CD14-PC5 or CD45-PC5 antibody were mixed and
incubated for 20 min in the dark at room temperature. The sample was then fixed with 100
μL Reagent 1 (IntraPrep™; Beckman Coulter) for 15 min, washed twice with fetal bovine
serum (FBS) (5 min, 300g), permeabilized, and lysed with 100 μL Reagent 2 (IntraPrep;
Beckman Coulter) for 5 min at room temperature. Either 20 μL MPO-FITC or 8 μL COX-2-
FITC antibody was added, and samples were incubated for 45 min in the dark at room
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temperature, washed twice with PBS, and resuspended in 500 μL FBS containing 0.5%
formaldehyde. Samples were analyzed within 30 min of preparation. Monocytes were
identified by CD14+ and CD45+ staining, and lymphocytes and granulocytes by CD45+
staining and light-scatter characteristics. Intracellular MPO and COX-2 were detected by
positive staining with anti-MPO and anti-COX-2 antibodies gated on CD14+ and CD45+
monocytes and CD45+ granulocytes, respectively. Two thousand monocyte events were
acquired in the list mode file from each sample. Results were expressed as percentage of
positive events and MFI for COX-2 and MFI for CD14, CD45, and MPO.
TWO-COLOR SAMPLE STAINING FOR PLATELET MARKERS
To prepare samples, we pipetted 2.5 μL well-mixed blood, 47.5 μL filtered FBS, and 10 μL
CD61-FITC and 10 μL CD62P-PE or 10 μL CD41-FITC and 10 μL CD154-PE. Samples were
mixed gently and kept in the dark at room temperature for 15 min, then diluted with 1.5 mL
FBS. Flow cytometric analysis was performed immediately. Ten thousand platelet events were
acquired in the list mode file from each sample. Platelets were identified and distinguished
from nonplatelet events (red blood cells and leukocytes) by their characteristic forward light
scatter (FS) vs SSC characteristics (log FS; log SSC) and their fluorescence from FL1 (CD61
and CD41), in the log-log dot plot of FS vs CD61 or CD41. Results for CD61 and CD41 were
expressed as MFI. Results for CD62P and CD154 were expressed as percentage of positive
events and MFI gated on CD61+ platelets and CD41+ platelets, respectively (Fig. 2A and B).
HETEROTYPIC PLATELET-LEUKOCYTE AGGREGATES
Monocytes were identified by a specific CD14-PC5 staining, and platelet-monocyte aggregates
(PMAs) were defined as CD14+ monocytes that are also CD41+. Results were expressed as
percentages of positive cells and MFI. Lymphocytes and granulocytes were identified by their
characteristic FS and SSC characteristics, and their aggregates with platelets (PLAs, PGAs)
defined by their positivity for CD41 (Fig. 3A and B). Results were expressed as percentages
of positive cells and MFI.
FLOW CYTOMETRY
Flow cytometric analysis was performed on an Epics™ XL™ (Beckman Coulter). A range of
strict internal quality assurance procedures were applied. The flow cytometer was calibrated
and verified daily with Flow Check™ and Flow Set™ fluorospheres (Beckman Coulter). A
stabilized whole blood sample (Immuno-Trol™ cells) was used weekly to verify 2- and 3-color
compensation settings; it also served as a positive procedure and reagent control for leukocyte
markers to confirm the stability of MFI measurements over time. Antibodies with the same lot
number and with the longest expiration dates were used to minimize between-batch variability.
On rare occasions when lots were changed, Immuno-Trol™ cells and at least 10 participants’
blood samples were used to test new reagents and compare with the previous lot. Sample data
were obtained and analyzed using EXPO32™ ADC software (Applied Cytometry Systems).
Data for the proportion of cells expressing the antigen of interest and the relative level of antigen
expression assessed by median fluorescence intensity were extracted from the acquired flow
cytometry list mode data files and transferred into Microsoft Excel files.
STUDY DESIGN
Three substudies were designed to evaluate sources of variation in flow cytometry
measurements. In the first (substudy 1), to estimate laboratory variability, blood samples from
20 subjects were selected by the laboratory for replicate testing on the same day. Each sample
was split into 2 aliquots, and measures obtained from independent flow cytometry analyses
were compared. Measurement variation estimated from these data cannot be attributed to
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variation in blood drawing, local processing, shipment procedures, laboratory handling and
analysis, or within-subject variation over time. In the within-visit reliability substudy (substudy
2), each field center drew duplicate blood tubes using a single venipuncture from a subset of
participants. The duplicate samples were sent to the flow cytometry laboratory under a blinded
quality control (QC) ID that was indistinguishable from other IDs. After the laboratory had
analyzed the paired samples (112 pairs), the results were compared to estimate the method
variability (i.e., variability in blood processing, shipping, and laboratory handling and
analysis). In the between-visit reliability substudy (substudy 3), each field center was asked to
recruit 15 volunteers to repeat the entire clinic visit within 4-8 weeks of their original visit.
Volunteers generally reflected the age, sex, and racial composition of the overall study. Again,
duplicate samples were submitted to the flow cytometry laboratory under a blinded QC ID.
Results from the paired samples (n = 55) were compared to estimate the method variability as
well as within-person variability over time.
STATISTICAL ANALYSIS
By treating the pair as a random effect in a linear mixed-effects model, we were able to partition
the total variance (σ2TOT) into a between-pair (or between-person, σ2BP) and within-pair
component of variance. The within-pair variance derived from the first split-sample substudy
1 corresponds to the laboratory variability. The within-pair component of variance derived
from the within-visit reliability substudy 2, in which duplicate samples were obtained from
participants on the same day, corresponds to an estimate of variation due to blood collection,
processing, and laboratory analysis (σ2e). In contrast, the within-pair component of variance
derived from the between-visit reliability substudy 3, in which duplicate samples were obtained
from participants at 2 separate visits, corresponds to an estimate of the within-person (biologic)
variation over time plus method variation (σ2WP + σ2e).
The proportion of the total variance attributable to between-person variability, or reliability
coefficient (R = σ2BP/σ2TOT), can be interpreted as the correlation between paired
measurements. Benchmarks for characterizing the adequacy of reliability were as follows
(32): slight reliability, 0-0.2; fair reliability, 0.21-0.4; moderate reliability, 0.41-0.6; substantial
reliability, 0.61-0.8; almost perfect reliability, 0.81-1.0. Based on our sample sizes of 112 and
55 for the 2 substudies, the 95% CI assuming a moderate reliability of 0.60 will have lower
limits of 0.48 and 0.44, respectively.
The CV was derived as the square-root of the within-pair component of variance divided by
the mean of the paired observations multiplied by 100. CV values >10% were considered cause
for concern.
Results
Laboratory variability was found to be low based on results from substudy 1 (see “Study
Design”) in which 20 split samples were analyzed on the same day. The laboratory CVs were
<10% for all monocyte and platelet markers (mean 3.6%, range 0%-14.5%) except for MPO.
In addition, reliability coefficients for all but 5 of the 35 flow cytometry parameters were >0.80.
The demographic characteristics of participants who contributed to the within-visit and
between-visit reliability substudies 1, 2, and 3 and to the overall ARIC Carotid MRI study are
listed in Table 1. The demographic composition of the within-visit reliability substudy was
similar to that of the ARIC Carotid MRI study participants: mean age was 71.7 years; 48%
were male; and 24% were African American. The volunteers in the between-visit reliability
substudy did not differ in age from the main study sample but included a higher percentage of
African American and men than the study sample (58% vs 48% male; 31% vs 25% African
American, respectively).
Catellier et al. Page 6













Table 2 gives summary QC duplicate sample results from the within-visit reliability substudy
2. In general, the percentage of positive events gated was highly reliable (R > 0.80) unless the
mean percentage gated was very near 0% or 100%, as was the case for COX-2 (98%), which
was intermediate in reliability (R = 0.69). All platelet markers had high reliability, with CD61
having the highest R value (R > 0.99). Ten percent was set as a goal for the upper limit of
processing CV. This goal was met for all but the percentage gated for CD62P and CD154, with
estimated CVs of 20% and 26%, respectively. Analysis of the 3 types of cell aggregates showed
low CV (<7%) and high reliability (R > 0.90).
The indices of repeatability for the QC replicates estimated from the between-visit reliability
substudy 3 are given in Table 3. The reliability coefficients derived from these repeat-visit QC
samples were 25% lower on average than those derived from the within-visit QC samples. The
reliability coefficients were substantially to highly repeatable (R > 0.60) for CD14, TLR-2,
CD162, CD61, CD62P, CD41, CD154, and all cell aggregates. In contrast, measurement of
TLR-4, COX-2, CD45, and MPO had slight to moderate reliability. The greatest decline in
reliability from the within-visit reliability to between-visit reliability substudy was for TLR-4,
COX-2, CD45, and MPO. The mean difference in CVs derived from the repeat-visit QC
samples and those derived from the within-visit QC samples was approximately 5%, with a
mean CV for the within- and between-visit reliability substudies of 6.7% and 11.6%,
respectively. As in the within-visit reliability substudy, CVs were <10%, with the exception
of the percentage of positive events for CD62P and CD154 and cell aggregates.
Discussion
We estimated various components of variation in whole blood monocyte and platelet markers
analyzed by flow cytometry within 24 h of blood collection, and we estimated repeatability of
measuring these analytes within the ARIC Carotid MRI population.
Results from substudy 2 of within-visit variability showed that both the percentage of positive
events and MFI were highly repeatable (R > 0.80) for monocyte and platelet markers and for
the heterotypic cell aggregates, when measured from replicate samples drawn from a single
venipuncture. The indices of repeatability from the between-visit reliability substudy 3, i.e.,
from the replicate samples drawn from 2 venipunctures taken 4-8 weeks apart, were 25% lower
on average than those derived from the within-visit QC replicates. The R values were
substantially to highly repeatable (R > 0.60) for all cell aggregates, platelet markers, and
monocyte CD14, TLR-2, and CD162. In contrast, measurements of monocyte TLR-4, COX-2,
and MPO had moderate reliability.
Results from the between-visit reliability substudy 3 show that sources of variation and
repeatability vary among the markers selected for the ARIC Carotid MRI study. Within-
individual variability can be in part explained by its natural biologic variation, but also to some
extent by shipping conditions, storage, and reagent variation. Our results show that among
monocyte markers, CD14, CD162, and TLR-2 had the highest R values. In view of the crucial
role of monocytes in atherosclerosis and PSGL-1 in hemostasis and inflammation, the high
reliability of these markers warrants their measurement in multicenter population studies. On
the other hand, COX-2, TLR-4, and MPO had the greatest within-individual variability. Several
factors may have contributed to this outcome. Both COX-2 and MPO are intracellular enzymes,
and their detection requires multiple steps of cell processing, permeabilization, multiple
washing, and centrifugation. It was expected that these methodological steps would contribute
to increased variability. Flow cytometric detection of intracellular MPO was shown to be
reliable using the same permeabilization protocol (33). The higher variability of monocyte
COX-2 is possibly the reflection of the high inducibility of this enzyme (34). It is interesting
that TLR-4 had a moderate R value, whereas both CD14 and TLR2 were highly repeatable.
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Both TLR receptors function to signal a ligand-binding event across a membrane, activating
NF-κB; TLR4 acts in conjunction with CD14, and it has been reported that there is cross-talk
between TLR4 and TLR2. It is possible that the greater variability of TLR4 may be in part
because it appears to function both at the membrane and intracellularly, whereas TLR2
functions at the cell membrane only (34).
Among the 4 selected platelet markers, CD61 had the highest R value (0.94). Platelet P-selectin
had good repeatability, whereas platelet CD40L had moderate R and high variance. Both P-
selectin and CD40L are released during platelet activation and cleaved from the membrane.
CD62P measurement appears to be more reliable than CD40L. The higher variance of CD40L
is likely because platelets do not contain significant amounts of CD40L. Importantly, the
rigorous standardization used for sample collection and shipping in our study was crucial for
generating reliable platelet measures.
In this study, the measurement of surface and intracellular antigen expression was assessed by
MFI. To minimize the influence of instrument settings and antibody staining variability on
MFI measurement, we applied strict QC approaches during the course of the study, which
resulted in high reliability of the relative staining intensities of analyzed markers. In terms of
quantitative flow cytometry, the higher level of standardization should include the use of
fluorescent bead calibration standards for antigen quantification (35-39).
In conclusion, high repeatability results for a selected platelet and monocyte markers in the
present study indicate that they can be reliably measured in multicenter studies with delayed
sample processing, when rigorous standardization of sample collection, shipping, and flow
cytometry procedures is applied. In view of the multiple roles of circulating platelets and
leukocytes and heterotypic cell aggregates in thrombosis and inflammation, their high
reliability supports ARIC’s analysis of the relationship between blood cells and cell aggregates
and atherosclerosis. It is reasonable to expect that their measurement will contribute to an
improved understanding of atherosclerotic disease.
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Fig. 1. Peripheral blood monocyte surface expression of PSGL-1 and TLR-2
The blood sample was stained with TLR-2-FITC, CD162-PE, and CD14-PC5. Monocytes were
identified by their respective SSC and CD14-PC5 staining characteristics. The gated events in
the monocyte region were then analyzed in a dual-fluorescence dot plot of CD162-PE vs
TLR-2-FITC.
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Fig. 2. Flow cytometric analysis of platelets
(A) Platelets were identified and distinguished from nonplatelet events (red blood cells and
leukocytes) by their respective FS vs SSC characteristics. (B) The gated events in region PLT
were displayed in a dual-fluorescence dot plot of CD61-FITC vs CD62P-PE. Events in the
region O2 that are double positive are considered to be activated. SS, side scatter.
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(A) Flow cytometric analysis of platelet-monocyte aggregates (PMAs) in whole blood
displayed in a dual-fluorescence dot plot of CD14-PC5 and CD41-FITC gated on monocytes.
Events in region CQ2 that are double positive are considered to be PMAs. Single-positive
events are platelet-free monocytes. (B) Comparison of light scatter characteristics of
CD14+CD41- and CD14+CD41+ populations. Population M represents platelet-free monocytes
and PMA platelet-monocyte aggregates.
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